Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694
+1 418-691-3154
Yves.Fradet@crchudequebec...

Latest news

344 entries « ‹ 2 of 35 › »

Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Journal Article

Clin Cancer Res, 28 (10), 2022.

Abstract | Links:

Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V

Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy

Journal Article

Clin Nutr ESPEN, 47 , 2022.

Abstract | Links:

Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype

Journal Article

Clin Transl Med, 12 (1), 2022.

Abstract | Links:

Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Velin D, Oster P, Raoult D, Ghiringhelli F, Boidot R, Chevrier S, Kysela DT, Brun YV, Falcone EL, Pilon G, Oñate FP, Gitton-Quent O, Le Chatelier E, Durand S, Kroemer G, Elkrief A, Marette A, Castagner B, Routy B

A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota

Journal Article

Cancer Discov, 12 (4), 2022.

Abstract | Links:

Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer

Journal Article

Asian J Androl, 24 (1), 2022.

Abstract | Links:

Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D

Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate

Journal Article

Cancers (Basel), 13 (24), 2021.

Abstract | Links:

Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, Fraser M, Bristow RG, van der Kwast T, Orain M, Brisson H, Benzerdjeb N, Hovington H, Bergeron A, Fradet Y, Têtu B, Saad F, Trudel D, Leblond F

Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens

Journal Article

J Biomed Opt, 26 (11), 2021.

Abstract | Links:

Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA

Journal Article

Int J Mol Sci, 22 (18), 2021.

Abstract | Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy

Journal Article

Can Urol Assoc J, 15 (10), 2021.

Abstract | Links:

Powles T, Matsubara N, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A,

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Journal Article

Lancet Oncol, 22 (7), 2021.

Abstract | Links:

344 entries « ‹ 2 of 35 › »
Signaler des ajouts ou des modifications

Active projects

  • Developement of a prostate cancer vaccine, from 2022-07-20 to 2023-07-19
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2023-06-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2024-01-14

Recently finished projects

  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate , from 2019-12-01 to 2022-11-30
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2023-04-30
  • Intégration de l'imagerie par résonance magnétique multiparamétrique dans la trajectoire diagnostique des patients avec suspicion de cancer de la prostate au CHU de Québec - Université Laval , from 2020-06-15 to 2022-09-30
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines , from 2022-03-22 to 2023-03-21
  • Prebiotics to enhance immunotherapy response in bladder cancer, from 2019-01-01 to 2021-07-31
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer, from 2017-04-01 to 2022-03-31
  • Testing of Biological Activity of DPX-Survivac in vivo in HLA-A1, HLA-A24 and HLA-B7 Transgenic mice, from 2021-05-28 to 2021-11-27
Data provided by the Université Laval research projects registery